
# SUSCEPTIBILITY PATTERNS OF — ALL INPATIENT — COMMON ISOLATES

## (including critical care units)

---

University of Toledo Medical Center

**Jan 2010 – December 2010**

## % SUSCEPTIBILITY OF COMMON GRAM NEGATIVE ISOLATES

URINARY AND NON-URINARY **ALL INPATIENT ISOLATES** (includes critical care)

**Jan 2010 – December 2010**

| ORGANISM | Total # tested | Aztreonam | Amikacin | Gentamicin | Tobramycin | Ampicillin | Amp/Sulbactam | Piperacillin / Tazobactam | Imipenem | Cefazolin | Cefepime | Ceftriaxone | Ciprofloxacin | TMX/SMX | ◇ % ESBL positive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acinetobacter baumannii | 40 | | 82 | 37 | 62 | | 60 | 38 | 60 | | 33 | | 30 | | |
| Enterobacter cloacae | 73 | 76 | 97 | 87 | 84 | | | 85 | 100 | | 97 | 81 | 85 | 80 | |
| Enterobacter aerogenes | 15* | 73 | 100 | 100 | 100 | | | 67 | 100 | | 100 | 73 | 93 | 100 | |
| Escherichia coli | 557 | 93 | 99 | 86 | 87 | 45 | 53 | 92 | 100 | 84 | 94 | 93 | 66 | 73 | 6 |
| Klebsiella pneumoniae | 196 | 86 | 99 | 90 | 85 | | 82 | 90 | 99 | 84 | 86 | 85 | 83 | 85 | 14 |
| Proteus mirabilis | 156 | 88 | 100 | 64 | 86 | 83 | 91 | 97 | 100 | 83 | 88 | 88 | 42 | 53 | |
| Pseudomonas aeruginosa | 225 | 51 | 92 | 65 | 85 | | | 81 | 80 | | 77 | | 64 | | |

◇ ESBL = extended spectrum beta-lactamase

***** – number is lower than CLSI recommended number of isolates to be reported; to be interpreted with caution

## % SUSCEPTIBILITY OF COMMON GRAM POSITIVE ISOLATES

URINARY AND NON-URINARY **ALL INPATIENT ISOLATES** (includes critical care)

**Jan 2010 – December 2010**

| ORGANISM | Total # tested | Ampicillin | Benzylpenicillin | Clindamycin | Gentamicin** | Linezolid | Oxacillin | Rifampicin** | Tetracycline | TMX/SMX | Vancomycin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Staphylococcus aureus (MSSA and MRSA) | 499 | | 6 | 59 | 98 | 100 | 38 | 94 | 95 | 93 | 100 |
| MRSA | 296 | | | 47 | 97 | 100 | | 99 | 96 | 88 | 100 |
| Coagulase-negative Staphylococcus | 293 | | 7 | 60 | 74 | 100 | 34 | 97 | 77 | 61 | 100 |
| Enterococcus faecalis | 204 | 97 | 97 | | | 99 | | | 25 | | 99 |
| Enterococcus faecium | 79 | 19 | 16 | | | 87 | | | 12 | | 37 |
| Streptococcus pneumoniae | 22* | | 59 | | | 100 | | | 86 | | 100 |

* number is lower than CLSI recommended number of isolates to be reported; to be interpreted with caution
** gentamicin and rifampin should never be used by themselves for treatment of Gram positive organisms


# SUSCEPTIBILITY PATTERNS OF COMMON ISOLATES

## — Critical Care —

University of Toledo Medical Center

**January 2010 – December 2010**

## % SUSCEPTIBILITY OF COMMON GRAM NEGATIVE ISOLATES

URINARY AND NON-URINARY IN-PATIENT ISOLATES – **Critical care**

**January 2010 – December 2010**

| ORGANISM | Total # tested | Aztreonam | Amikacin | Gentamicin | Trobramycin | Ampicillin | Amp/Sulbactam | Pip/Tazobactam | Imipenem/ Meropenem | Cefazolin | Cefepime | Ceftriaxone | Ciprofloxacin | TMX/SMX | ◇ % ESBL positive |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acinetobacter baumannii | 10* | | 83 | 40 | 50 | | 60 | 30 | 60 | | 20 | | 30 | | |
| Enterobacter cloacae | 6* | 86 | 100 | 86 | 86 | | | 93 | 100 | | 93 | 93 | 86 | 86 | |
| Enterobacter aerogenes | 15* | 67 | 100 | 100 | 100 | | | 67 | 100 | | 100 | 67 | 100 | 100 | |
| Escherichia coli | 67 | 90 | 100 | 85 | 84 | 39 | 46 | 86 | 100 | 82 | 91 | 91 | 54 | 69 | 8 |
| Klebsiella pneumoniae | 36 | 75 | 97 | 86 | 78 | | 72 | 86 | 97 | 75 | 75 | 75 | 67 | 81 | 25 |
| Proteus mirabilis | 21* | 72 | 100 | 57 | 81 | 67 | 76 | 95 | 100 | 67 | 72 | 72 | 33 | 43 | |
| Pseudomonas aeruginosa | 64 | 39 | 84 | 50 | 73 | | | 67 | 65 | | 69 | | 53 | | |

◇ ESBL = extended spectrum beta-lactamase

* Number of isolates is too small to interpret

## % SUSCEPTIBILITY OF COMMON GRAM POSITIVE ISOLATES

URINARY AND NON-URINARY IN-PATIENT ISOLATES – **Critical Care**

**January 2010 – December 2010**

| ORGANISM | Total # tested | Ampicillin | Penicillin | Clindamycin | Gentamicin | Linezolid | Oxacillin | Rifampin | Tetracycline | TMX/SMX | Vancomycin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Staphylococcus aureus (MSSA and MRSA) | 74 | | | 34 | 96 | 100 | 29 | 100 | 97 | 85 | 100 |
| MRSA | 53 | | | 21 | 92 | 100 | | 100 | 96 | 81 | 100 |
| Coagulase-negative Staphylococcus | 42 | | 2 | 45 | 64 | 100 | 26 | 95 | 72 | 55 | 100 |
| Enterococcus faecalis | 22* | 100 | 100 | | | 100 | | | 27 | | 96 |
| Enterococcus faecium | 19* | 5 | 0 | | | 95 | | | 5 | | 21 |
| Streptococcus pneumoniae | **0** | | | | | | | | | | |

* number is lower than CLSI recommended number of isolates to be reported (30); to be interpreted with caution

** gentamicin and rifampin should never be used by themselves for treatment of Gram positive organisms